Benzinga | Jul 30, 2021 07:51AM EDT

Goldman Sachs Downgrades Agios Pharmaceuticals to Sell, Lowers Price Target to $39

Goldman Sachs analyst Salveen Richter downgrades Agios Pharmaceuticals (NASDAQ:AGIO) from Neutral to Sell and lowers the price target from $58 to $39.